(Q77751582)

English

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group

scientific article published on 01 December 1998

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

Içli F

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Aykan F

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Uner A

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Demirkazik A

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Ozet A

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Ozgüroğlu M

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Taş F

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Akbulut H

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Firat D

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 December 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

83

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

2475-2480

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II Trial of Etoposide (V), Adriamycin (A), and Cisplatinum (P) in Patients with Metastatic Gastric Cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF)

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Nativity, complications, and pathology are determinants of surgical results for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(19981215)83:12<2475::AID-CNCR10>3.0.CO;2-H

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q77751582&oldid=1584731243"